Primary tuberculosis of the nose is very rare. We report a case of a 35-year-old woman who presented with bilateral nasal obstruction and epistaxis of 3 months' duration but who was otherwise healthy. She was diagnosed with primary nasal septal tuberculosis and was treated with antituberculosis DOTS (directly observed treatment, short course) therapy for 6 months with complete recovery. Given the resurgence of tuberculosis in recent times, it is important that clinicians remain aware of this rare and treatable clinical entity.
Introduction
Primary tuberculosis of the nose is exceedingly rare, with fewer than 100 cases having been reported in the literature. Nasal involvement of tuberculosis was fi rst described in Venice by Giovanni Morgagni 1 in 1761, but it was not until 1876 that primary nasal disease was described by Clarke 2 in an address to the Pathological Society of London. We report a case of primary septal tuberculosis. Details of the case are presented to highlight the rarity of primary tuberculosis at this site, and to stress the special care required in its identifi cation and subsequent treatment.
Case report
A 35-year-old woman presented to the ENT outpatient department of SKIMS Medical College with a chief complaint of nasal blockage of 3 months' duration that was progressively increasing. Th e patient had a history of epistaxis (2 episodes) and hyposmia, but no history of trauma, mucopurulent rhinorrhea, facial pain, hemoptysis, loss of weight/appetite, or evening rise in temperature. She had been treated by a private practitioner for chronic allergic rhinosinusitis for 1 month but with no relief.
On physical examination, a slight visible expansion of the dorsum of the nose was observed. Anterior rhinoscopy revealed the presence of a bilateral septal bulge that almost completely obstructed the lumen of the nose. Th e septal bulge was fi rm on palpation, and the overlying mucoperichondrium showed an ulcer on the left side of the nares. Th e patient's family history was not signifi cant. Her personal history was also not signifi cant, as she was a nonsmoker and not a snuff user.
Results of the patient's complete blood count were normal, and her erythrocyte sedimentation rate was 35 mm/1st hour. Her sputum was negative for acid-fast bacilli (3 morning samples). Results of her enzyme-linked immunosorbent assay for tuberculosis (IgM) were borderline (0.993 IU), but her Mantoux test was strongly positive (25 mm). Her enzyme-linked immunosorbent assay for HIV was negative.
Th e patient's chest x-ray (posteroanterior view) was normal. Computed tomography (CT) of the nose and paranasal sinuses showed cartilaginous thickening of the nasal septum and the suggestion of surface ulceration (fi gure 1). No perforation or bony destruction was seen. Sinuses were clear and well pneumatized.
A punch biopsy was taken from the septal ulcer and sent for histopathologic examination. Microscopy showed ulceration of the mucosa, with multiple coalescing granulomas of epitheloid cells with Langhans giant cells; these fi ndings indicated tuberculous infl ammation (fi gure 2). Th e patient was subsequently examined thoroughly for any other foci of tuberculosis in the body, but none were found.
On the basis of histopathology and other laboratory values, we established a diagnosis of primary nasal septal tuberculosis. Th e patient was categorized as having category III tuberculosis and started on a three-drug losis. Th e diagnosis is oft en based on histopathologic fi ndings. 9 Among the treatment options for nasal tuberculosis are drug therapy, surgical excision, diathermy, cautery, and radiotherapy. However, Goguen and Karmody reported that the recurrence rate following excision was greater than 50%. 7 Current recommendations for drug therapy are the same as for other category III tuberculosis lesions, i.e., an initial 2-month phase with a four-drug regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, followed by a continuation phase with two drugs (isoniazid and rifampin for 4 months or isoniazid and ethambutol for 6 months, depending on the individual antituberculosis DOTS (directly observed treatment, short course) regimen of isoniazid, rifampin and pyrazinamide for 2 months, followed by a two-drug regimen of isoniazid and rifampin thrice weekly for 4 months. 3 She responded quickly and showed improvement in clinical symptoms and physical signs. Aft er completion of the antituberculosis therapy, a CT scan showed complete resolution of the septal lesion (fi gure 3).
Discussion
Nasal tuberculosis is a rare, chronic, granulomatous infection caused by Mycobacterium tuberculosis. It can occur either as a primary infection or secondary to an infection at another site. Th e rarity of the disease can be explained by the protective function provided by the ciliary action of the nasal mucosa, the bactericidal properties of the nasal secretions, and the protective mechanisms of nasal vibrissae. Th e infection can be introduced into the nose by inhalation of infected droplets or dust, and by inoculation via the fi nger. 4 Th e usual initial symptoms of nasal tuberculosis are unilateral or bilateral nasal obstruction that is frequently associated with mucoid or mucopurulent rhinorrhea and postnasal drip. Epistaxis is sometimes frequent but brief. Pain is usually absent. It is most common in immunocompromised patients and in those who live in crowded and unhygienic conditions. Th ere is a distinct female preponderance (female-to-male ratio is 3:1), and the mean age at diagnosis has been reported to be 40 years. 5 Onodi (quoted by Chamerlain 6 ) described three basic types of nasal tuberculosis: ulcerative, infi ltrative, and proliferative. Goguen and Karmody found that exophytic, granular lesions were more common than the ulcerative and infi ltrative types. 7 In decreasing order of frequency, involved sites include the anterior septum, turbinate, and nasal fl oor. Bilateral involvement occurs with septal lesions. A direct extension of infection from nose to ethmoid sinus may occur. Th e organism may spread into the sphenoid, frontal, or maxillary sinuses through the sinus ducts. Th e orbit may be invaded, and infection can extend to the cranial cavity. 8 Smears of acid-fast bacilli and cultures tend to be negative in nasal tubercu- 
Figure 2. A: Photoomicrograph shows the nasal mucosa with coalescing granuloma of epitheloid cells and Langhans giant cells (H&E, original magnifi cation ×100). B: Th is photomicrograph shows caseating granuloma surrounded by Langhans giant cells and lymphocytes (H&E, original magnifi cation ×400).
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patient's requirements, culture results, and sensitivity rates when available). Ethambutol in the initial phase may be omitted for patients who have limited, noncavitary, smear-negative pulmonary tuberculosis and are known to be HIV-negative; patients with less severe forms of extrapulmonary tuberculosis, such as our patient; and patients with known susceptible strains. 3 Th e possibility of HIV positivity must be considered in all cases of nasal tuberculosis, as 5 to 10% of immunocompromised patients are infected by Mycobacterium species, and 70% of patients with AIDS and tuberculosis have extrapulmonary tuberculosis. 10 
